- GSK Modern Slavery Act statement 2023 (PDF - 142KB)
- GSK Modern Slavery Act Statement 2022 (PDF - 194KB)
- GSK Modern Slavery Act Statement 2021 (PDF - 211KB)
- GSK Modern Slavery Act Statement 2020 (PDF - 191KB)
- GSK Modern Slavery Act Statement 2019 (PDF - 215KB)
- GSK Modern Slavery Act Statement 2018 (PDF - 145KB)
- GSK Modern Slavery Act Statement 2017 (PDF - 209KB)
- GSK binding corporate rules (PDF - 216KB)
- GSK binding corporate rules_Czech (PDF - 223KB)
- GSK binding corporate rules_Danish (PDF - 205KB)
- GSK binding corporate rules_Dutch (PDF - 208KB)
- GSk binding corporate rules_Finnish (PDF - 170KB)
- GSK binding corporate rules_French (PDF - 239KB)
- GSk binding corporate rules_German (PDF - 211KB)
- GSK binding corporate rules_Greek (PDF - 235KB)
- GSK binding corporate rules_Italian(PDF - 220KB)
- GSK binding corporate rules_Polish (PDF - 225KB)
- GSK binding corporate rules_Portuguese (PDF - 250KB)
- GSK binding corporate rules_Spanish (PDF - 222KB)
- GSK binding corporate rules_Swedish (PDF - 218KB)
- GSK plc 2023 form sd conflict minerals disclosure (PDF - 126KB)
- GSK plc 2022 form sd conflict minerals disclosure (PDF - 131KB)
- Glaxosmithkline plc 2021 form sd conflict minerals disclosure (PDF - 89.9KB)
- Glaxosmithkline plc 2020 form sd conflict minerals disclosure (PDF - 121KB)
- Glaxosmithkline plc 2019 form sd conflict minerals disclosure (PDF- 161KB)
- Glaxosmithkline plc 2018 form sd conflict minerals disclosure (PDF - 289KB)
- Glaxosmithkline plc 2017 form sd conflict minerals disclosure (PDF - 241KB)
- Glaxosmithkline plc 2016 form sd conflict minerals disclosure (PDF - 1.2MB)
- Glaxosmithkline plc 2015 form sd conflict minerals disclosure (PDF - 130KB)
- Glaxosmithkline plc 2014 form sd conflict minerals disclosure (PDF - 122KB)
- GSK Euro Medium Term Note Programme – Offering Memorandum – August 2024 (PDF 508KB)
- GSK Euro Medium Term Note Programme – Supplementary Prospectus – December 2023
- GSK Euro Medium Term Note Programme – prospectus document – August 2023
- GSK Euro Medium Term Note Programme - Third Supplementary Prospectus November 2022
- GSK Euro Medium Term Note Programme – Further Supplementary Prospectus November 2022
- GSK Euro Medium Term Note Programme – Supplementary Prospectus November 2022 (PDF 110KB)
- GSK Euro Medium Term Note Programme – prospectus document – September 2022 (PDF - 1MB)
- GlaxoSmithKline Euro Medium Term Note Programme – prospectus document – December 2021 (PDF - 940KB)
- GlaxoSmithKline Euro Medium Term Note Programme – prospectus document – May 2021 (PDF - 923KB)
- Glaxosmithkline Euro Medium Term Note Programme – (PDF - 60KB) Supplementary Prospectus November 2020
- Glaxosmithkline Euro Medium Term Note Programme Prospectus Document 2020 (PDF - 1.5MB)
- GlaxoSmithKline Euro Medium Term Note Programme – Supplementary Prospectus 2020 (PDF - 73KB)
- Glaxosmithkline Euro Medium Term Note Programme – Prospectus Document 2019 (PDF - 1.3MB)
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2018 (PDF - 1.1MB)
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2017 (PDF - 506KB)
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2016 (PDF - 464KB)
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2015 (PDF - 470KB)
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2014 (PDF - 462KB)
- 2024 Half Year Results and Interim Management Report GlaxoSmithKline Capital plc (PDF - 245KB)
- 2023 Annual Report Glaxosmithkline Capital plc (PDF - 526 KB)
- 2023 Half Year Results and Interim Management Report Glaxosmithkline Capital plc (PDF - 3.3MB)
- 2022 Annual Report GlaxoSmithKline Capital plc (PDF - 447KB)
- 2022 Half Year Results and Interim Management Report Glaxosmithkline Capital Plc (PDF - 325KB)
- 2021 Annual Report GlaxoSmithKline Capital plc (PDF - 245KB)
- 2020 Annual Report Glaxosmithkline Capital Plc (PDF - 430KB)
- 2020 Half Year Results And Interim Management Report Glaxosmithkline Capital Plc (PDF - 229KB)
- 2019 Annual Report GlaxoSmithKline Capital plc (PDF - 596KB)
- 2019 Half Year Results And Interim Management Report Glaxosmithkline Capital Plc (PDF - 188KB)
- 2018 Annual Report GlaxoSmithKline Capital plc (PDF - 420KB)
- 2018 Half Year Results And Interim Management Report Glaxosmithkline Capital Plc (PDF - 427KB)
- 2017 Annual Report GlaxoSmithKline Capital plc (PDF - 741KB)
- 2017 Half Year Results and Interim Management Report GlaxoSmithKline Capital plc (PDF - 301KB)
- 2016 Annual Report GlaxoSmithKline Capital plc (PDF - 7.6MB)
- 2016 Half Year Results and Interim Management Report GlaxoSmithKline Capital plc (PDF - 360KB)
- 2015 Annual Report GlaxoSmithKline Capital plc (PDF - 640KB)
- 2015 Half Year Results and Interim Management Report GlaxoSmithKline Capital plc (PDF - 342KB)
- 2014 Annual Report GlaxoSmithKline Capital plc (PDF - 7.9MB)
- 2014 Half Year Results and Interim Management Report GlaxoSmithKline Capital plc (PDF - 68KB)
- 2013 Annual Report GlaxoSmithKline Capital plc (PDF - 331KB)
- 2013 Half Year Results and Interim Management Report GlaxoSmithKline Capital plc (PDF - 2.1MB)
- 2012 Annual Report GlaxoSmithKline Capital plc (PDF - 540KB)
- 2012 Half Year Results and Interim Management Report GlaxoSmithKline Capital plc (PDF - 182KB)
- 2011 Annual Report GlaxoSmithKline Capital plc (PDF - 617KB)
- 2011 Half Year Results and Interim Management Report GlaxoSmithKline Capital plc (PDF - 301KB)
- 2010 Annual Report GlaxoSmithKline Capital plc (PDF - 4.9MB)
- 2009 Annual Report GlaxoSmithKline Capital plc (PDF - 2.9MB)
- 2008 Annual Report GlaxoSmithKline Capital plc (PDF - 3.5MB)